Abstract: A method for analyzing cell free DNA (cfDNA) from the bloodstream of a cancer patient is provided. In some embodiments, the method may comprise sequencing at least part of the coding sequences of TP53 and KRAS in a sample of the cfDNA, analyzing the sequences to identify nucleotide transversions in the coding sequences of the genes, relative to reference sequences of the genes. In some embodiments, the method may comprise counting the total number of identified nucleotide transversions. The presence of nucleotide transversions indicates that the patient will be more responsive to the immune checkpoint inhibitor, whereas a decreased number of transversions or no transversios indicates that the patient will be less responsive to the immune checkpoint inhibitor.

Abstract: A method for analyzing cell free DNA (cfDNA) from the bloodstream of a cancer patient is provided. In some embodiments, the method may comprise sequencing at least part of the coding sequences of TP53 and KRAS in a sample of the cfDNA, analyzing the sequences to identify nucleotide transversions in the coding sequences of the genes, relative to reference sequences of the genes. In some embodiments, the method may comprise counting the total number of identified nucleotide transversions. The presence of nucleotide transversions indicates that the patient will be more responsive to the immune checkpoint inhibitor, whereas a decreased number of transversions or no transversios indicates that the patient will be less responsive to the immune checkpoint inhibitor.

Abstract: A method for analyzing cell free DNA (cfDNA) from the bloodstream of a cancer patient is provided. In some embodiments, the method may comprise sequencing at least part of the coding sequences of TP53 and KRAS in a sample of the cfDNA, analyzing the sequences to identify nucleotide transversions in the coding sequences of the genes, relative to reference sequences of the genes. In some embodiments, the method may comprise counting the total number of identified nucleotide transversions. The presence of nucleotide transversions indicates that the patient will be more responsive to the immune checkpoint inhibitor, whereas a decreased number of transversions or no transversios indicates that the patient will be less responsive to the immune checkpoint inhibitor.

Abstract: A method for analyzing cell free DNA (cfDNA) from the bloodstream of a cancer patient is provided. In some embodiments, the method may comprise sequencing at least part of the coding sequences of TP53 and KRAS in a sample of the cfDNA, analyzing the sequences to identify nucleotide transversions in the coding sequences of the genes, relative to reference sequences of the genes. In some embodiments, the method may comprise counting the total number of identified nucleotide transversions. The presence of nucleotide transversions indicates that the patient will be more responsive to the immune checkpoint inhibitor, whereas a decreased number of transversions or no transversions indicates that the patient will be less responsive to the immune checkpoint inhibitor.

Abstract: Systems and methods for monitoring a paging signal from a mobile switch to a cellular transmitter for occurrences of congestion. The system includes a switch; a cell site in communication with the switch, for broadcasting a page received from the switch to a cellular device configured to receive the page; and a monitoring module in communication with the switch for monitoring occurrences of paging congestion between the switch and the cell site.

Abstract: Systems and methods for monitoring a paging signal from a mobile switch to a cellular transmitter for occurrences of congestion. The system includes a switch; a cell site in communication with the switch, for broadcasting a page received from the switch to a cellular device configured to receive the page; and a monitoring module in communication with the switch for monitoring occurrences of paging congestion between the switch and the cell site.

Abstract: Systems and methods for monitoring a paging signal from a mobile switch to a cellular transmitter for occurrences of congestion. The system includes a switch; a cell site in communication with the switch, for broadcasting a page received from the switch to a cellular device configured to receive the page; and a monitoring module in communication with the switch for monitoring occurrences of paging congestion between the switch and the cell site.

Abstract: A system and method to monitor call data for a number of cellular phones simultaneously and in real time. A UNIX-based diagnosis software allows flexibility and versatility in call monitoring and functionality testing of a cellular switch. The diagnosis software scans and parses, in real time, the call data received from a cellular switch so as to enable a technician to monitor (and diagnose) the radio environment of a cell when a call is placed from that cell. Additional cellular switch-specific data such as, for example, radio channels assigned to a cell phone call, handoff signals communicated, power level for a radio link, etc., may also be monitored on a per-call basis. Thus, simultaneous and real time testing of more than one radio link can be performed by a technician in a cellular service provider's network during, for example, routine maintenance of a cellular switch, installation and testing of a new switch, addition or reconfiguration of a cell site, etc.

Abstract: Systems and methods for monitoring a paging signal from a mobile switch to a cellular transmitter for occurrences of congestion. The system includes a switch; a cell site in communication with the switch, for broadcasting a page received from the switch to a cellular device configured to receive the page; and a monitoring module in communication with the switch for monitoring occurrences of paging congestion between the switch and the cell site.